Comparing DNA Isolation and Preparation Protocols for Dried Blood Spots in the Context of Genomic Newborn Screening
- PMID: 40981305
- PMCID: PMC12452450
- DOI: 10.3390/ijns11030075
Comparing DNA Isolation and Preparation Protocols for Dried Blood Spots in the Context of Genomic Newborn Screening
Abstract
Due to rapid technical advancements and increasing cost-effectiveness, the potential application of next-generation sequencing (NGS) in newborn screening (NBS) has raised great interest worldwide. Genomic NBS offers the possibility to improve current NBS programs when applied as follow-up tier, and, as first-tier, allows for inclusion of conditions lacking a detectable biomarker for conventional NBS. Obtaining enough high-quality DNA from typically limited dried blood spot (DBS) material to meet NGS requirements can be challenging. Selecting a DNA isolation method for genomic NBS requires balancing technical performance and laboratory feasibility with optimal cost-effectiveness. Ten DNA isolation protocols, including two column-based, five lysis-based, and three semi-automated magnetic bead-based protocols, were evaluated on technical outcomes and performance in targeted amplicon sequencing. Additionally, estimated costs, hands-on time, turnaround time, scalability, and plastic footprint were assessed. Although technical outcomes, including yield, purity, and molecular weight, differed between methods, qualitative results in amplicon sequencing, as defined by read output, mapping, and coverage depth, were found sufficient and comparable for various protocols. In conclusion, both technical requirements and operational parameters are crucial when selecting a DNA isolation protocol and will depend on the NGS application as well as the NBS approach, as either first-tier or follow-up tier.
Keywords: DBS; DNA isolation; DNA preparation; NBS; NGS; dried blood spot; genomic newborn screening; newborn screening; next-generation sequencing.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures
References
-
- Therrell B.L., Padilla C.D., Borrajo G.J.C., Khneisser I., Schielen P., Knight-Madden J., Malherbe H.L., Kase M. Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023) Int. J. Neonatal Screen. 2024;10:38. doi: 10.3390/ijns10020038. - DOI - PMC - PubMed
-
- Borte S., von Dobeln U., Fasth A., Wang N., Janzi M., Winiarski J., Sack U., Pan-Hammarstrom Q., Borte M., Hammarstrom L. Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood. 2012;119:2552–2555. doi: 10.1182/blood-2011-08-371021. - DOI - PubMed
-
- Taylor J.L., Lee F.K., Yazdanpanah G.K., Staropoli J.F., Liu M., Carulli J.P., Sun C., Dobrowolski S.F., Hannon W.H., Vogt R.F. Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. Clin. Chem. 2015;61:412–419. doi: 10.1373/clinchem.2014.231019. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
